{"address1": "441 Ninth Avenue", "address2": "14th Floor", "city": "New York", "state": "NY", "zip": "10001", "country": "United States", "phone": "646 661 7661", "fax": "646 661 4027", "website": "https://www.ovidrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.", "fullTimeEmployees": 23, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.", "age": 71, "title": "CEO & Chairman", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 1030026, "exercisedValue": 0, "unexercisedValue": 671250}, {"maxAge": 1, "name": "Mr. Jeffrey A. Rona", "age": 56, "title": "Chief Business and Financial Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 761235, "exercisedValue": 0, "unexercisedValue": 104909}, {"maxAge": 1, "name": "Ms. Meg  Alexander", "title": "President & COO", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dirk  Haasner", "age": 59, "title": "Senior Vice President of Global Manufacturing & CMC QA", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 416952, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julia  Tsai Ph.D.", "age": 49, "title": "Senior Vice President of Clinical Development", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Toshiya  Nishi D.V.M.", "title": "Head of Epilepsy Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Zhong  Zhong Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Manal  Morsy M.B.A., M.D., PH.D.", "title": "Chief Regulatory Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Victoria  Fort", "title": "Senior Vice President of Corporate Affairs & Corporate Strategy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tom  Parry", "title": "Vice President of Research and Early Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.3119, "open": 0.3252, "dayLow": 0.3001, "dayHigh": 0.3271, "regularMarketPreviousClose": 0.3119, "regularMarketOpen": 0.3252, "regularMarketDayLow": 0.3001, "regularMarketDayHigh": 0.3271, "payoutRatio": 0.0, "beta": 0.291, "forwardPE": -0.7941026, "volume": 334769, "regularMarketVolume": 334769, "averageVolume": 432093, "averageVolume10days": 604400, "averageDailyVolume10Day": 604400, "bid": 0.3, "ask": 0.3928, "bidSize": 3, "askSize": 1, "marketCap": 22011928, "fiftyTwoWeekLow": 0.3, "fiftyTwoWeekHigh": 3.45, "priceToSalesTrailing12Months": 38.89033, "fiftyDayAverage": 0.55686, "twoHundredDayAverage": 0.944635, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -16308071, "profitMargins": 0.0, "floatShares": 50468940, "sharesOutstanding": 71075000, "sharesShort": 1064983, "sharesShortPriorMonth": 991311, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.015, "heldPercentInsiders": 0.16285999, "heldPercentInstitutions": 0.56448, "shortRatio": 3.79, "shortPercentOfFloat": 0.0182, "impliedSharesOutstanding": 79859600, "bookValue": 0.961, "priceToBook": 0.3222685, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -25975000, "trailingEps": -0.37, "forwardEps": -0.39, "enterpriseToRevenue": -28.813, "enterpriseToEbitda": 0.282, "52WeekChange": -0.89836067, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 0.3097, "targetHighPrice": 4.0, "targetLowPrice": 2.0, "targetMeanPrice": 3.2, "targetMedianPrice": 3.0, "recommendationMean": 1.14286, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 53075000, "totalCashPerShare": 0.747, "ebitda": -57772000, "totalDebt": 14755000, "quickRatio": 5.044, "currentRatio": 5.316, "totalRevenue": 566000, "debtToEquity": 21.627, "revenuePerShare": 0.008, "returnOnAssets": -0.30899, "returnOnEquity": -0.33883, "grossProfits": 566000, "freeCashflow": -29904624, "operatingCashflow": -55956000, "revenueGrowth": -0.465, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -143.71053, "financialCurrency": "USD", "symbol": "OVID", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Ovid Therapeutics Inc.", "longName": "Ovid Therapeutics Inc.", "preMarketChange": 0.0153999925, "preMarketChangePercent": 4.9725513, "preMarketPrice": 0.3251, "regularMarketChange": -0.0021999776, "regularMarketDayRange": "0.3001 - 0.3271", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 432093, "fiftyTwoWeekLowChange": 0.0097, "fiftyTwoWeekLowChangePercent": 0.032333333, "fiftyTwoWeekRange": "0.3 - 3.45", "fiftyTwoWeekHighChange": -3.1403, "fiftyTwoWeekHighChangePercent": -0.9102319, "fiftyTwoWeekChangePercent": -89.83607, "earningsTimestamp": 1741694401, "earningsTimestampStart": 1747053000, "earningsTimestampEnd": 1747398600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.37, "epsForward": -0.39, "epsCurrentYear": -0.56, "priceEpsCurrentYear": -0.55303574, "fiftyDayAverageChange": -0.24716002, "fiftyDayAverageChangePercent": -0.44384587, "twoHundredDayAverageChange": -0.63493496, "twoHundredDayAverageChangePercent": -0.67214847, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.1 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1493991000000, "regularMarketChangePercent": -0.7053471, "regularMarketPrice": 0.3097, "corporateActions": [], "preMarketTime": 1743595201, "regularMarketTime": 1743537600, "exchange": "NMS", "messageBoardId": "finmb_288870432", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "displayName": "Ovid Therapeutics", "trailingPegRatio": null}